As our DCAF7 inhibitors demonstrated the capacity to modulate basal TFEB levels and lysosomal activity, we next sought to explore the utility of these compounds in the setting of viral infection, where the DCAF7-dependent degradation of TFEB is markedly augmented. The gene discussed is DCAF7; the disease is viral infectious disease.